European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update
M Rouprêt, T Seisen, AJ Birtle, O Capoun… - European urology, 2023 - Elsevier
Abstract Context The European Association of Urology (EAU) guidelines panel on upper
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …
urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in …
Artificial intelligence aids in development of nanomedicines for cancer management
P Tan, X Chen, H Zhang, Q Wei, K Luo - Seminars in cancer biology, 2023 - Elsevier
Over the last decade, the nanomedicine has experienced unprecedented development in
diagnosis and management of diseases. A number of nanomedicines have been approved …
diagnosis and management of diseases. A number of nanomedicines have been approved …
[HTML][HTML] ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …
strong evidence base for use in patients with cancer. The European Society for Medical …
[HTML][HTML] Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma
Y Loriot, N Matsubara, SH Park… - … England Journal of …, 2023 - Mass Medical Soc
Background Erdafitinib is a pan–fibroblast growth factor receptor (FGFR) inhibitor approved
for the treatment of locally advanced or metastatic urothelial carcinoma in adults with …
for the treatment of locally advanced or metastatic urothelial carcinoma in adults with …
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
T Powles, J Bellmunt, E Comperat… - Annals of …, 2022 - annalsofoncology.org
Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …
cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018 …
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a …
M Javle, S Roychowdhury, RK Kelley… - The Lancet …, 2021 - thelancet.com
Background Treatment options are sparse for patients with advanced cholangiocarcinoma
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …
after progression on first-line gemcitabine-based therapy. FGFR2 fusions or rearrangements …
[HTML][HTML] TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based …
ST Tagawa, AV Balar, DP Petrylak… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-
based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited …
based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited …
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Next-generation sequencing (NGS) allows sequencing of a high number of nucleotides in a
short time frame at an affordable cost. While this technology has been widely implemented …
short time frame at an affordable cost. While this technology has been widely implemented …
The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma
R Cathomas, A Lorch, HM Bruins, EM Compérat… - European urology, 2022 - Elsevier
Context Treatment of metastatic urothelial carcinoma is currently undergoing a rapid
evolution. Objective This overview presents the updated European Association of Urology …
evolution. Objective This overview presents the updated European Association of Urology …
European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines
JA Witjes, HM Bruins, R Cathomas, EM Compérat… - European urology, 2021 - Elsevier
Context This overview presents the updated European Association of Urology (EAU)
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …
guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …